Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 6/20 | 0.47 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2405758 | 0.81 | KMT2A (0.41) | KMT2ACHRM1CCR5SIGMAR1ALDH1A1 | |
| SCHEMBL2404975 | 0.81 | KMT2A (0.41) | KMT2ACHRM1CCR5ALDH1A1NPC1 | |
| SCHEMBL2404021 | 0.80 | SIGMAR1 (0.62) | KMT2ACCR5SIGMAR1 | |
| SCHEMBL7120048 | 0.79 | CTBP2 (0.51) | KMT2ACTBP2ALDH1A1MAPTNPC1 | |
| SCHEMBL13434079 | 0.78 | CCR5 (0.63) | CHRM1CCR5SIGMAR1KCNH2 | |
| SCHEMBL23761932 | 0.77 | CCR5 (0.65) | KMT2ACHRM1CCR5SIGMAR1ALDH1A1 | |
| SCHEMBL2405195 | 0.77 | HTR2A (0.47) | KMT2ACHRM1ALDH1A1MAPT | |
| SCHEMBL6926430 | 0.76 | KMT2A (0.48) | KMT2ACHRM1CCR5SIGMAR1ALDH1A1 | |
| SCHEMBL13478880 | 0.75 | ALDH1A1 (0.58) | KMT2ACCR5ALDH1A1KCNH2 | |
| SCHEMBL2407533 | 0.73 | KCNH2 (0.49) | KMT2ACCR5SIGMAR1KCNH2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | KMT2A 253/4885CHRM1 152/4885CCR5 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.